Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart R Lipsitz

Showing results (431-440 of 437) with videos related to

Pageof 44
Sort By:
You have reached the last page of results.This site can display upto 437 results.
Circulation|October 20, 2025
Direct Therapeutic Modulation of RYR2 Activity by CMYA5Fujian Lu, Zexuan Wu, Shaopeng Chi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomesSteven E Lipshultz, Tracie L Miller, Rebecca E Scully, et al.
Pediatrics|November 21, 2012
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac OutcomesSteven E Lipshultz, Tracie L Miller, Stuart R Lipsitz, et al.
The Lancet. Oncology|September 21, 2010
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trialSteven E Lipshultz, Rebecca E Scully, Stuart R Lipsitz, et al.
Cancer|July 18, 2013
Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemiaSteven E Lipshultz, Stuart R Lipsitz, Jeffery L Kutok, et al.
The New England Journal of Medicine|November 6, 2014
Changes in medical errors after implementation of a handoff programAmy J Starmer, Nancy D Spector, Rajendu Srivastava, et al.
JAMA Pediatrics|February 28, 2017
Families as Partners in Hospital Error and Adverse Event SurveillanceAlisa Khan, Maitreya Coffey, Katherine P Litterer, et al.
Pageof 44

Showing results (431-440 of 437) with videos related to

Sort By:
Pageof 44
You have reached the last page of results.This site can display upto 437 results.
Circulation|October 20, 2025
Direct Therapeutic Modulation of RYR2 Activity by CMYA5Fujian Lu, Zexuan Wu, Shaopeng Chi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomesSteven E Lipshultz, Tracie L Miller, Rebecca E Scully, et al.
Pediatrics|November 21, 2012
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac OutcomesSteven E Lipshultz, Tracie L Miller, Stuart R Lipsitz, et al.
The Lancet. Oncology|September 21, 2010
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trialSteven E Lipshultz, Rebecca E Scully, Stuart R Lipsitz, et al.
Cancer|July 18, 2013
Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemiaSteven E Lipshultz, Stuart R Lipsitz, Jeffery L Kutok, et al.
The New England Journal of Medicine|November 6, 2014
Changes in medical errors after implementation of a handoff programAmy J Starmer, Nancy D Spector, Rajendu Srivastava, et al.
JAMA Pediatrics|February 28, 2017
Families as Partners in Hospital Error and Adverse Event SurveillanceAlisa Khan, Maitreya Coffey, Katherine P Litterer, et al.
Pageof 44